7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-class oral small...

7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-concept oral small...

7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines HOUSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...

7 Hills Pharma Appoints Lionel D. Lewis as Chief Medical Officer HOUSTON, July 24, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, today announced the...

7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, announced today the formation...